Luis A. Diaz Jr.

Luis Diaz is a leader in precision oncology who discovered that mismatch repair deficiency (dMMR/MSI-H) predicts exceptional response to immune checkpoint inhibitors across tumor types. His work led to the first pan-cancer FDA approval of pembrolizumab for MSI-H tumors regardless of tissue origin—a landmark in precision medicine.

Luis Diaz是精准肿瘤学的领导者，他发现错配修复缺陷（dMMR/MSI-H）预测对免疫检查点抑制剂的卓越反应跨越肿瘤类型。他的工作导致了pembrolizumab针对MSI-H肿瘤的首个泛癌种FDA批准——精准医学的里程碑。